Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients

Renal Failure

Volumn 37, Issue 6, 2015, Pages 951-956

  Unver, Suat ^a   Kavlak, Ela ^b   Gümüsel, Hilal Kurtoglu ^b   Celikbilek, Fatma ^c,d   Esertas, Kenan ^b   Muftuoglu, Tuba ^e   Kirilmaz, Ata ^b  

^a ISTANBUL AYDIN UNIVERSITY   (Turkey)

^b Istanbul Private Erdem Hospital   (Turkey)

^c USKUDAR UNIVERSITY   (Turkey)

^d Department of Hemodialysis ^*  (Turkey)

^e GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

FGF 23; hemodialysis; left ventricular hypertrophy; volume overload

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN A1C; PARATHYROID HORMONE; PHOSPHORUS; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHRONIC DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIALYSIS EQUIPMENT AND SUPPLIES; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE WALL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERVOLEMIA; INTRACARDIAC ECHOCARDIOGRAPHY; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ULTRAFILTRATION; UPREGULATION; URINE VOLUME; ADVERSE EFFECTS; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; WATER-ELECTROLYTE IMBALANCE;

ADULT; AGED; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROBLAST GROWTH FACTORS; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; WATER-ELECTROLYTE IMBALANCE;

EID: 84941560263     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2015.1052945     Document Type: Article

References (24)

1. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47 (1): 186-192
2. Foley RN, Parfrey PS. Risk factors for cardiac morbidity and mortality in dialysis patients. Curr Opin Nephrol Hypertens. 1994; 3 (6): 608-614
3. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010; 5 (5): 805-813
4. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994; 4 (7): 1486-1490
5. McMahon LP, Parfrey PS.: Cardiovascular aspects of chronic kidney disease. In: Brenner BM., ed. Brenner and Rectors The Kidney. 8th ed. Philadelphia: Saunders Elsevier; 2008: 1697-1727
6. Tsai YC, Chiu YW, Tsai JC, et al. Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol. 2015; 10 (1): 39-46
7. Russo D, Battaglia Y. Clinical significance of FGF-23 in patients with CKD. Int J Nephrol. 2011; 2011: 364890
8. Komaba H. CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23 Klothoaxis in CKD-MBD. Clin Calcium. 2010; 20 (7): 1028-1036
9. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358-367
10. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450-458
11. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension. 1987; 9 (2 Pt 2): II19-26
12. Laddha M, Sachdeva V, Diggikar PM, Satpathy PK, Kakrani AL. Echocardiographic assessment of cardiac dysfunction in patients of end stage renal disease on hemodialysis. J Assoc Physicians India. 2014; 62 (1): 28-32.
13. Charytan D. Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Curr Opin Nephrol Hypertens. 2014; 23: 578-585
14. Davenport A. Will incremental hemodialysis preserve residual function and improve patient survival? Semin Dial. 2015; 28 (1): 16-19
15. Leunissen KML. Fluid status in hemodialysed patients. Nephrol Dial Transplant. 1995; 10: 153-155
16. Charra B. Dry weight in dialysis: the history of a concept. Nephrol Dial Transplant. 1998; 13: 1882-1885
17. Luik AJ, Charra B, Katzarski K, et al. Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Blood Purif. 1998; 16: 197-209
18. Wizemann V, Schilling M. Dilemma of assessing volume state: The use and limitations of a clinical score. Nephrol Dial Transplant. 1995; 10: 2114-2117
19. Weiner DE, Brunelli SM, Hunt A, et al. Improving clinical outcomes among hemodialysis patients: a proposal for a "volume first" approach from the chief medical officers of us dialysis providers. Am J Kidney Dis. 2014; 64 (5): 685-695
20. Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. Ther Apher Dial. 2007; 111: S32-37
21. Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: The atherosclerosis risk in communities study. J Am Heart Assoc. 2014; 3 (3): e000936
22. Agarwal I, Ide N, Ix JH, et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc. 2014; 3: e000584
23. Diniz H, Frazão JM. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder. Nefrologia. 2013; 33 (6): 835-844
24. Sany D, Elsawy AE, Aziz A, et al. The value of serum FGF-23 as a cardiovascular marker in HD patients. Saudi J Kidney Dis Transpl. 2014; 25 (1): 44-52